Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 41 for your search:
Cancer Type/Condition:
Non-Hodgkin lymphoma, child
Stage/Subtype:
stage III childhood lymphoblastic lymphoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
2.
Phase III Randomized Study of Glutamic Acid in Reducing Vincristine-Related Peripheral Neurotoxicity in Young Patients Undergoing Vincristine-Containing Treatment for Wilms' Tumor, Rhabdomyosarcoma, Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
3 to 20
Sponsor:
NCI
Protocol IDs:
HLMCC-0402
, NCT00369564, ACCL 0731
3.
Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases or Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MSKCC-95024
, NCI-V95-0685, NCT00002663
4.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
5.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
6.
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 17
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
AP23573-07-110
, SUN08-01, NCT00704054
7.
Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
CPMC-IRB-AAAA5571
, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
8.
Phase II Study of Umbilical Cord Blood as a Source of Hematopoietic Stem Cells for Transplantation in Children With Malignant or Non-Malignant Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
PSCI-2003-232
, NCT00084695
9.
Phase II Study of a Myeloablative Preparative Regimen Comprising Busulfan, Melphalan, and Thiotepa Followed By Autologous Peripheral Blood Stem Cell Transplantation in Patients With Hodgkin's or Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years and younger
Sponsor:
NCI
Protocol IDs:
OHSU-HEM-04083-L
, OHSU-IRB-248, NCT00238433
10.
Phase II Study of Myeloablative Preparative Regimen Comprising Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Patients Undergoing Unrelated Umbilical Cord Blood Transplantation for Hematologic Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
45 and under
Sponsor:
NCI
Protocol IDs:
UMN-2005LS043
, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
11.
Study of Combination Chemotherapy Comprising Cyclophosphamide, and Fludarabine and Radiotherapy Followed By Cyclosporine and Mycophenolate Mofetil in Patients With Hematologic Malignancies, Metastatic Breast Cancer, or Renal Cell Cancer Undergoing Allogeneic Stem Cell Transplantation
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
NCI
Protocol IDs:
UMN-2001LS058
, UMN-MT2001-10, NCT00303719
12.
Phase II Study of Nonmyeloablative Conditioning Regimen Comprising Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Umbilical Cord Blood Transplantation and Post-Transplant Immunosuppression Comprising Cyclosporine and Mycophenolate Mofetil in Patients With Hematologic Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
NCI
Protocol IDs:
UMN-2005LS036
, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
13.
Phase II Study of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Non-Hodgkin's or Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Under 70
Sponsor:
NCI
Protocol IDs:
UMN-2005LS048
, UMN-0508M72589, UMN-MT2004-24, NCT00345865
14.
Rituximab-HCVAD in Patients With B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 to 60
Sponsor:
Other
Protocol IDs:
2005-0054
, NCT00290498
15.
Phase II Study of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer or Other Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
70 years old and under
Sponsor:
NCI
Protocol IDs:
CCCWFU-29506
, CCCWFU 29506, NCT00453206, CCCWFU-IRB00001366
16.
Phase II Study of Graft-Versus-Host Prophylaxis Comprising Sirolimus, Tacrolimus, and Anti-Thymocyte Globulin in Patients Undergoing Unrelated-Donor Hematopoietic Cell Transplantation For Hematological Malignancy
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
2 and over
Sponsor:
NCI
Protocol IDs:
CHNMC-06141
, 06141, NCT00589563
17.
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
ID02-230
, NCT00671658
18.
Phase II Study of Unrelated Umbilical Cord Blood Transplantation in Combination With a Myeloablative Preparative Regimen Comprising Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Patients With Hematological Diseases
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
6 months to 45 years
Sponsor:
NCI
Protocol IDs:
FHCRC-2010.00
, 6095, NCT00719888
19.
Phase II Study of Early Administration of Low-Dose Anti-Thymocyte Globulin followed by Low-Dose Cyclophosphamide, Busulfan, and Fludarabine to Optimize Outcome of Reduced-Intensity Conditioning for Allogeneic Peripheral Blood Progenitor Cell Transplantation From a Matched Related Donor in Patients With Lymphomas, Hodgkins Disease, Leukemias, Myelodysplastic Syndrome or Renal Cell Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
BMTGG-NSH-807
, NSH 807, NCT00787761
20.
Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Leukemia or Lymphoma (BMT CTN #0604)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
1 to 70
Sponsor:
NCI, NHLBI
Protocol IDs:
606
, U01 HL069294, NCT00864227
21.
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
12 to 40
Sponsor:
Other
Protocol IDs:
2006-0375
, NCT00866749
22.
Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
P2 L-D AB
, NCT00917826
23.
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
0 to 65
Sponsor:
Other
Protocol IDs:
2009-0266
, NCT01010217
24.
CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
0 to 26
Sponsor:
Other
Protocol IDs:
CHNY 525
, AAAB2879, NCT01049854
25.
Unrelated Donor Transplant for Malignant and Non-Malignant Disorders
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
CHNY-02-516
, IRB# AAAB3095, NCT01050439
Select All on Page
1
Help with Results
